[Skip to Navigation]
Sign In
Comment & Response
November 2018

Oral Contraceptive Progestin and Estrogen Use and Increases in Breast, Ovarian, and Endometrial Cancers—Reply

Author Affiliations
  • 1Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Human Health Services, Rockville, Maryland
JAMA Oncol. 2018;4(11):1623-1624. doi:10.1001/jamaoncol.2018.4166

In Reply We thank Dr Grant for the interest in our work. The associations between oral contraceptive (OC) use and the cancers on which we report have been established with extensive research; the protective effect of OC use on endometrial and ovarian cancer risk is well documented.1 Thus, the goal of our study was to evaluate the consistency of OC use–cancer risk associations across modifiable risk factors.2 The points raised about our article include potential confounding by (1) menopausal hormone therapy (MHT) use and (2) hysterectomy.

Add or change institution